Chemokines and their Receptors Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Chemokines and their Receptors

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: keokalani'nui who wrote (45)	5/6/2003 3:17:52 PM
From: keokalani'nui	Read Replies (1) of 70

[CCR2] INCY announces its first internal drug platform is the development of an oral CCR2 antagonist for inflammation; RA, IBD, MS and possibly artherosclerosis. Have had a compound into rodents and primates, data to be presented at DB conf today. Hope is for it to be 'nominated' for preclinical development in '03. Believe they have leapfrogged several companies, including some large pharma, in the medicinal chemistry.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next